thalidomide-peg-2-c2-nh2

Thalidomide-O-amido-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology[1].

Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, combines a Thalidomide-based cereblon ligand with a two-unit PEG linker for use in PROTAC technology[1].

Thalidomide-O-amido-PEG3-C2-NH2 TFA, a synthesized E3 ligase ligand-linker conjugate, combines the cereblon ligand based on Thalidomide and a 2-unit PEG linker for use in PROTAC technology[1].

Thalidomide-O-amido-PEG2-C2-NH2 TFA (E3 Ligase Ligand-Linker Conjugates 24 TFA) 包含基于 Thalidomide 的 cereblon 配体和 2 个单元的 PEG linker，是一种合成的 E3 连接酶配体-linker 偶联物。

Thalidomide-O-amido-PEG-C2-NH2 hydrochloride 包含基于 Thalidomide 的 cereblon 配体和 1 个 linker，是一种合成的 E3 连接酶配体-linker 偶联物。它可用于 PROTAC 的合成分子。

Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride 包含一个 E3 连接酶配体和一个 linker。 Thalidomide-O-amido-PEG2-C2-NH2 盐酸盐可用作治疗癌症的免疫调节剂。

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthesized conjugate compound known as an E3 ligase ligand-linker. It incorporates a cereblon ligand based on Thalidomide and a 3-unit PEG linker. This compound is specifically designed for use in PROTAC technology applications.

Thalidomide-O-amido-PEG2-C2-NH2, which combines an E3 ligase ligand with a linker, serves as an immunomodulator for cancer treatment.

Thalidomide-O-amido-PEG-C2-NH2 is a synthesized conjugate formulation designed as an E3 ligase ligand-linker conjugate. It incorporates a cereblon ligand based on Thalidomide and a linker component commonly utilized in PROTAC technology.

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthetic conjugate compound that combines a Thalidomide-based cereblon ligand and a linker, which is commonly utilized in PROTAC technology. This compound acts as a connector between the target protein and the E3 ligase, facilitating targeted protein degradation.